Fischer Medical Ventures Ltd: Intrinsic Value & Share Price Analysis

Share Price and Basic Stock Data

Last Updated: August 29, 2025, 1:26 pm

Market Cap	6,849 Cr.
Current Price	1,056
High / Low	1,085/590
Stock P/E	1,036
Book Value	52.9
Dividend Yield	0.00 %
ROCE	1.07 %
ROE	0.70 %
Face Value	10.0
PEG Ratio	19.66

Quick Insight

Fischer Medical Ventures Ltd, operating in the inorganic chemicals sector, currently shows a Price-to-Earnings ratio of 1,041 and a Return on Equity of 0.70%, indicating potential undervaluation and inefficiency in capital utilization. With a Return on Capital Employed at 1.07% and a healthy Operating Profit Margin of 18.17%, the company seems to struggle with optimizing its capital resources effectively. Moreover, a high Price-to-Book Value of 16.95x suggests a premium valuation relative to its book value. The company's comfortable Interest Coverage Ratio of 10.30x, however, indicates strong ability to meet debt obligations. Overall, Fischer Medical Ventures faces challenges in profitability and valuation metrics, warranting a closer examination of its operational efficiency and growth strategies.

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Fischer Medical Ventures Ltd

Competitors of Fischer Medical Ventures Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
Fischer Medical Ventures Ltd	6,849 Cr.	1,056	1,085/590	1,036	52.9	0.00 %	1.07 %	0.70 %	10.0
Emmessar Biotech & Nutrition Ltd	13.5 Cr.	27.0	64.0/25.8	33.8	15.4	0.00 %	12.6 %	4.23 %	10.0
Cochin Minerals & Rutile Ltd	230 Cr.	294	415/238	11.0	211	2.72 %	23.3 %	15.0 %	10.0
Archean Chemical Industries Ltd	8,105 Cr.	656	764/408	36.7	152	0.46 %	16.0 %	12.0 %	2.00
Alufluoride Ltd	341 Cr.	436	544/341	17.7	132	0.69 %	23.6 %	20.8 %	10.0
Industry Average	5,659.25 Cr	585.52		157.19	156.59	0.46%	13.47%	10.14%	7.82

All Competitor Stocks of Fischer Medical Ventures Ltd

Quarterly Result

Metric	Sep 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025
Sales	0.00	20.79	10.12	39.66	11.75	49.17	23.44
Expenses	0.00	18.28	10.33	39.16	11.38	46.68	19.18
Operating Profit	0.00	2.51	-0.21	0.50	0.37	2.49	4.26
OPM %		12.07%	-2.08%	1.26%	3.15%	5.06%	18.17%
Other Income	0.00	0.47	0.69	0.05	0.38	0.06	7.36
Interest	0.00	0.05	0.13	0.05	0.07	0.23	0.67
Depreciation	0.00	0.18	0.28	0.29	0.56	0.51	0.77
Profit before tax	0.00	2.75	0.07	0.21	0.12	1.81	10.18
Tax %		6.18%	271.43%	-38.10%	350.00%	27.62%	50.79%
Net Profit	0.00	2.59	-0.12	0.29	-0.29	1.31	5.01
EPS in Rs	0.00	0.48	-0.02	0.05	-0.05	0.21	0.77

Last Updated: August 19, 2025, 3:40 pm

Below is a detailed analysis of the quarterly data for Fischer Medical Ventures Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:

For Sales, as of Jun 2025, the value is 23.44 Cr.. The value appears to be declining and may need further review. It has decreased from 49.17 Cr. (Mar 2025) to 23.44 Cr., marking a decrease of 25.73 Cr..
For Expenses, as of Jun 2025, the value is 19.18 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 46.68 Cr. (Mar 2025) to 19.18 Cr., marking a decrease of 27.50 Cr..
For Operating Profit, as of Jun 2025, the value is 4.26 Cr.. The value appears strong and on an upward trend. It has increased from 2.49 Cr. (Mar 2025) to 4.26 Cr., marking an increase of 1.77 Cr..
For OPM %, as of Jun 2025, the value is 18.17%. The value appears strong and on an upward trend. It has increased from 5.06% (Mar 2025) to 18.17%, marking an increase of 13.11%.
For Other Income, as of Jun 2025, the value is 7.36 Cr.. The value appears strong and on an upward trend. It has increased from 0.06 Cr. (Mar 2025) to 7.36 Cr., marking an increase of 7.30 Cr..
For Interest, as of Jun 2025, the value is 0.67 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.23 Cr. (Mar 2025) to 0.67 Cr., marking an increase of 0.44 Cr..
For Depreciation, as of Jun 2025, the value is 0.77 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 0.51 Cr. (Mar 2025) to 0.77 Cr., marking an increase of 0.26 Cr..
For Profit before tax, as of Jun 2025, the value is 10.18 Cr.. The value appears strong and on an upward trend. It has increased from 1.81 Cr. (Mar 2025) to 10.18 Cr., marking an increase of 8.37 Cr..
For Tax %, as of Jun 2025, the value is 50.79%. The value appears to be increasing, which may not be favorable. It has increased from 27.62% (Mar 2025) to 50.79%, marking an increase of 23.17%.
For Net Profit, as of Jun 2025, the value is 5.01 Cr.. The value appears strong and on an upward trend. It has increased from 1.31 Cr. (Mar 2025) to 5.01 Cr., marking an increase of 3.70 Cr..
For EPS in Rs, as of Jun 2025, the value is 0.77. The value appears strong and on an upward trend. It has increased from 0.21 (Mar 2025) to 0.77, marking an increase of 0.56.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: June 16, 2025, 1:28 pm

Metric	Mar 2023	Mar 2024	Mar 2025
Sales	0	21	111
Expenses	0	19	108
Operating Profit	0	2	3
OPM %	11%	9%	3%
Other Income	0	0	1
Interest	0	0	0
Depreciation	0	0	2
Profit before tax	0	2	2
Tax %		13%	45%
Net Profit	-0	2	1
EPS in Rs	-2.33	0.34	0.23
Dividend Payout %	0%	0%	18%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2024-2025
YoY Net Profit Growth (%)	-50.00%
Change in YoY Net Profit Growth (%)	0.00%

Fischer Medical Ventures Ltd has shown a consistent positive trend in YoY Net Profit Growth (%) in the last 1 years from 2024-2025 to 2024-2025.

Growth

Compounded Sales Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	428%

Compounded Profit Growth
10 Years:	%
5 Years:	%
3 Years:	%
TTM:	-20%

Stock Price CAGR
10 Years:	78%
5 Years:	90%
3 Years:	162%
1 Year:	69%

Return on Equity
10 Years:	%
5 Years:	%
3 Years:	%
Last Year:	1%

Last Updated: Unknown

Balance Sheet

Last Updated: July 25, 2025, 1:18 pm

Month	Mar 2023	Mar 2024	Mar 2025
Equity Capital	0.17	54	64
Reserves	-0	28	274
Borrowings	1	2	85
Other Liabilities	0	4	34
Total Liabilities	0	86	457
Fixed Assets	0	15	24
CWIP	0	0	1
Investments	0	1	11
Other Assets	0	70	422
Total Assets	0	86	457

Below is a detailed analysis of the balance sheet data for Fischer Medical Ventures Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:

For Equity Capital, as of Mar 2025, the value is 64.00 Cr.. The value appears strong and on an upward trend. It has increased from 54.00 Cr. (Mar 2024) to 64.00 Cr., marking an increase of 10.00 Cr..
For Reserves, as of Mar 2025, the value is 274.00 Cr.. The value appears strong and on an upward trend. It has increased from 28.00 Cr. (Mar 2024) to 274.00 Cr., marking an increase of 246.00 Cr..
For Borrowings, as of Mar 2025, the value is 85.00 Cr.. The value appears to be increasing, which may not be favorable. Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has increased from 2.00 Cr. (Mar 2024) to 85.00 Cr., marking an increase of 83.00 Cr..
For Other Liabilities, as of Mar 2025, the value is 34.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 4.00 Cr. (Mar 2024) to 34.00 Cr., marking an increase of 30.00 Cr..
For Total Liabilities, as of Mar 2025, the value is 457.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 86.00 Cr. (Mar 2024) to 457.00 Cr., marking an increase of 371.00 Cr..
For Fixed Assets, as of Mar 2025, the value is 24.00 Cr.. The value appears strong and on an upward trend. It has increased from 15.00 Cr. (Mar 2024) to 24.00 Cr., marking an increase of 9.00 Cr..
For CWIP, as of Mar 2025, the value is 1.00 Cr.. The value appears strong and on an upward trend. It has increased from 0.00 Cr. (Mar 2024) to 1.00 Cr., marking an increase of 1.00 Cr..
For Investments, as of Mar 2025, the value is 11.00 Cr.. The value appears strong and on an upward trend. It has increased from 1.00 Cr. (Mar 2024) to 11.00 Cr., marking an increase of 10.00 Cr..
For Other Assets, as of Mar 2025, the value is 422.00 Cr.. The value appears strong and on an upward trend. It has increased from 70.00 Cr. (Mar 2024) to 422.00 Cr., marking an increase of 352.00 Cr..
For Total Assets, as of Mar 2025, the value is 457.00 Cr.. The value appears strong and on an upward trend. It has increased from 86.00 Cr. (Mar 2024) to 457.00 Cr., marking an increase of 371.00 Cr..

Notably, the Reserves (274.00 Cr.) exceed the Borrowings (85.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2024	Mar 2025
Cash from Operating Activity +	-8	-86
Cash from Investing Activity +	-29	-125
Cash from Financing Activity +	37	315
Net Cash Flow	1	103

Free Cash Flow

Month	Mar 2023	Mar 2024	Mar 2025
Free Cash Flow	-1.00	0.00	-82.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2023	Mar 2024	Mar 2025
Debtor Days	345	398	251
Inventory Days			36
Days Payable			82
Cash Conversion Cycle	345	398	205
Working Capital Days	324	498	107
ROCE %		5%	1%

Financial Efficiency Indicators Chart

No valid data available for the Shareholding

Shareholding Pattern Chart

No. of Shareholders

This stock is not held by any mutual fund.

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 25	Mar 24	Mar 23
FaceValue	10.00	10.00	10.00
Basic EPS (Rs.)	0.22	1.65	-2.12
Diluted EPS (Rs.)	0.22	1.08	-2.12
Cash EPS (Rs.)	0.52	0.37	-2.12
Book Value[Excl.RevalReserv]/Share (Rs.)	52.95	15.16	-15.47
Book Value[Incl.RevalReserv]/Share (Rs.)	52.95	15.16	-15.47
Revenue From Operations / Share (Rs.)	17.35	3.92	10.44
PBDIT / Share (Rs.)	0.75	0.44	0.88
PBIT / Share (Rs.)	0.49	0.40	0.88
PBT / Share (Rs.)	0.42	0.39	-0.07
Net Profit / Share (Rs.)	0.26	0.34	-2.12
NP After MI And SOA / Share (Rs.)	0.18	0.34	-2.12
PBDIT Margin (%)	4.34	11.25	8.46
PBIT Margin (%)	2.86	10.38	8.46
PBT Margin (%)	2.44	10.06	-0.72
Net Profit Margin (%)	1.53	8.75	-20.33
NP After MI And SOA Margin (%)	1.09	8.75	-20.33
Return on Networth / Equity (%)	0.35	2.26	0.00
Return on Capital Employeed (%)	0.84	2.64	4.97
Return On Assets (%)	0.26	2.12	-10.32
Long Term Debt / Equity (X)	0.05	0.00	-2.15
Total Debt / Equity (X)	0.17	0.00	-2.15
Asset Turnover Ratio (%)	0.40	0.48	0.00
Current Ratio (X)	4.48	18.37	5.18
Quick Ratio (X)	4.37	17.20	5.18
Interest Coverage Ratio (X)	10.30	34.92	0.92
Interest Coverage Ratio (Post Tax) (X)	4.63	28.19	-1.21
Enterprise Value (Cr.)	5536.51	3303.93	1.98
EV / Net Operating Revenue (X)	50.01	157.47	11.03
EV / EBITDA (X)	1151.30	1399.44	130.31
MarketCap / Net Operating Revenue (X)	51.74	159.28	8.05
Price / BV (X)	16.95	41.20	-5.43
Price / Net Operating Revenue (X)	51.74	159.31	8.05
EarningsYield	0.00	0.00	-0.02

After reviewing the key financial ratios for Fischer Medical Ventures Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 1.65 (Mar 24) to 0.22, marking a decrease of 1.43.
For Diluted EPS (Rs.), as of Mar 25, the value is 0.22. This value is below the healthy minimum of 5. It has decreased from 1.08 (Mar 24) to 0.22, marking a decrease of 0.86.
For Cash EPS (Rs.), as of Mar 25, the value is 0.52. This value is below the healthy minimum of 3. It has increased from 0.37 (Mar 24) to 0.52, marking an increase of 0.15.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 52.95. It has increased from 15.16 (Mar 24) to 52.95, marking an increase of 37.79.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 52.95. It has increased from 15.16 (Mar 24) to 52.95, marking an increase of 37.79.
For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 17.35. It has increased from 3.92 (Mar 24) to 17.35, marking an increase of 13.43.
For PBDIT / Share (Rs.), as of Mar 25, the value is 0.75. This value is below the healthy minimum of 2. It has increased from 0.44 (Mar 24) to 0.75, marking an increase of 0.31.
For PBIT / Share (Rs.), as of Mar 25, the value is 0.49. This value is within the healthy range. It has increased from 0.40 (Mar 24) to 0.49, marking an increase of 0.09.
For PBT / Share (Rs.), as of Mar 25, the value is 0.42. This value is within the healthy range. It has increased from 0.39 (Mar 24) to 0.42, marking an increase of 0.03.
For Net Profit / Share (Rs.), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.26, marking a decrease of 0.08.
For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 0.18. This value is below the healthy minimum of 2. It has decreased from 0.34 (Mar 24) to 0.18, marking a decrease of 0.16.
For PBDIT Margin (%), as of Mar 25, the value is 4.34. This value is below the healthy minimum of 10. It has decreased from 11.25 (Mar 24) to 4.34, marking a decrease of 6.91.
For PBIT Margin (%), as of Mar 25, the value is 2.86. This value is below the healthy minimum of 10. It has decreased from 10.38 (Mar 24) to 2.86, marking a decrease of 7.52.
For PBT Margin (%), as of Mar 25, the value is 2.44. This value is below the healthy minimum of 10. It has decreased from 10.06 (Mar 24) to 2.44, marking a decrease of 7.62.
For Net Profit Margin (%), as of Mar 25, the value is 1.53. This value is below the healthy minimum of 5. It has decreased from 8.75 (Mar 24) to 1.53, marking a decrease of 7.22.
For NP After MI And SOA Margin (%), as of Mar 25, the value is 1.09. This value is below the healthy minimum of 8. It has decreased from 8.75 (Mar 24) to 1.09, marking a decrease of 7.66.
For Return on Networth / Equity (%), as of Mar 25, the value is 0.35. This value is below the healthy minimum of 15. It has decreased from 2.26 (Mar 24) to 0.35, marking a decrease of 1.91.
For Return on Capital Employeed (%), as of Mar 25, the value is 0.84. This value is below the healthy minimum of 10. It has decreased from 2.64 (Mar 24) to 0.84, marking a decrease of 1.80.
For Return On Assets (%), as of Mar 25, the value is 0.26. This value is below the healthy minimum of 5. It has decreased from 2.12 (Mar 24) to 0.26, marking a decrease of 1.86.
For Long Term Debt / Equity (X), as of Mar 25, the value is 0.05. This value is below the healthy minimum of 0.2. It has increased from 0.00 (Mar 24) to 0.05, marking an increase of 0.05.
For Total Debt / Equity (X), as of Mar 25, the value is 0.17. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 0.17, marking an increase of 0.17.
For Asset Turnover Ratio (%), as of Mar 25, the value is 0.40. It has decreased from 0.48 (Mar 24) to 0.40, marking a decrease of 0.08.
For Current Ratio (X), as of Mar 25, the value is 4.48. This value exceeds the healthy maximum of 3. It has decreased from 18.37 (Mar 24) to 4.48, marking a decrease of 13.89.
For Quick Ratio (X), as of Mar 25, the value is 4.37. This value exceeds the healthy maximum of 2. It has decreased from 17.20 (Mar 24) to 4.37, marking a decrease of 12.83.
For Interest Coverage Ratio (X), as of Mar 25, the value is 10.30. This value is within the healthy range. It has decreased from 34.92 (Mar 24) to 10.30, marking a decrease of 24.62.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 4.63. This value is within the healthy range. It has decreased from 28.19 (Mar 24) to 4.63, marking a decrease of 23.56.
For Enterprise Value (Cr.), as of Mar 25, the value is 5,536.51. It has increased from 3,303.93 (Mar 24) to 5,536.51, marking an increase of 2,232.58.
For EV / Net Operating Revenue (X), as of Mar 25, the value is 50.01. This value exceeds the healthy maximum of 3. It has decreased from 157.47 (Mar 24) to 50.01, marking a decrease of 107.46.
For EV / EBITDA (X), as of Mar 25, the value is 1,151.30. This value exceeds the healthy maximum of 15. It has decreased from 1,399.44 (Mar 24) to 1,151.30, marking a decrease of 248.14.
For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 51.74. This value exceeds the healthy maximum of 3. It has decreased from 159.28 (Mar 24) to 51.74, marking a decrease of 107.54.
For Price / BV (X), as of Mar 25, the value is 16.95. This value exceeds the healthy maximum of 3. It has decreased from 41.20 (Mar 24) to 16.95, marking a decrease of 24.25.
For Price / Net Operating Revenue (X), as of Mar 25, the value is 51.74. This value exceeds the healthy maximum of 3. It has decreased from 159.31 (Mar 24) to 51.74, marking a decrease of 107.57.
For EarningsYield, as of Mar 25, the value is 0.00. This value is below the healthy minimum of 5. There is no change compared to the previous period (Mar 24) which recorded 0.00.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Fischer Medical Ventures Ltd as of August 30, 2025 is: 313.04

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of August 30, 2025, Fischer Medical Ventures Ltd is Overvalued by 70.36% compared to the current share price 1,056.00

Intrinsic Value of Fischer Medical Ventures Ltd as of August 30, 2025 is: 477.99

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of August 30, 2025, Fischer Medical Ventures Ltd is Overvalued by 54.74% compared to the current share price 1,056.00

Last 5 Year EPS CAGR: 52.69%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock is trading at a low valuation with an average P/B ratio of 0.59 and average Dividend Yield of 7.23%. The company has higher reserves (100.67 cr) compared to borrowings (29.33 cr), indicating strong financial stability. The company has shown consistent growth in sales (44.00 cr) and profit (1.33 cr) over the years.	The stock has a low average ROCE of 2.00%, which may not be favorable. The stock has a high average Working Capital Days of 309.67, which may not be favorable. The stock has a high average Cash Conversion Cycle of 316.00, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Fischer Medical Ventures Ltd:
1. Net Profit Margin: 1.53%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 0.84% (Industry Average ROCE: 13.47%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 0.35% (Industry Average ROE: 10.14%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 4.63
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 4.37
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 1 (Industry average Stock P/E: 157.19)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0.17
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Fischer Medical Ventures Ltd. is a Public Limited Listed company incorporated on 22/03/1993 and has its registered office in the State of Maharashtra, India. Company's Corporate Identification Number(CIN) is L86900MH1993PLC288371 and registration number is 288371. Currently Company is involved in the business activities of Wholesale of scientific, medical and surgical machinery and equipment. Company's Total Operating Revenue is Rs. 5.22 Cr. and Equity Capital is Rs. 63.80 Cr. for the Year ended 31/03/2025.

INDUSTRY	ADDRESS	CONTACT
Chemicals - Inorganic - Others	104, First Floor, Raghuleela Mega Mall, Mumbai Maharashtra 400067	fischerchemicltd@gmail.com https://www.fischerchemic.in

Management
Name	Position Held
Mr. Ravindran Govindan	Chairman & Managing Director
Mr. Jeena Dineshchandra Suthar	Independent Director
Mr. Sanjay Jayantilal Jain	Independent Director
Mr. Svetlana Rao	Whole Time Executive Director
Mr. Khairy Jamaluddin Abu Bakkar	Independent Director
Mr. Jacob Thomas	Independent Director
Mr. Roberto M Pagdanganan	Independent Director

FAQ

What is the intrinsic value of Fischer Medical Ventures Ltd?

Fischer Medical Ventures Ltd's intrinsic value (as of 29 August 2025) is 313.04 which is 70.36% lower the current market price of ₹1,056.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's ₹6,849 Cr. market cap, FY2025-2026 high/low of 1,085/590, reserves of ₹274 Cr, and liabilities of 457 Cr.

What is the Market Cap of Fischer Medical Ventures Ltd?

The Market Cap of Fischer Medical Ventures Ltd is 6,849 Cr..

What is the current Stock Price of Fischer Medical Ventures Ltd as on 29 August 2025?

The current stock price of Fischer Medical Ventures Ltd as on 29 August 2025 is 1,056.

What is the High / Low of Fischer Medical Ventures Ltd stocks in FY 2025-2026?

In FY 2025-2026, the High / Low of Fischer Medical Ventures Ltd stocks is 1,085/590.

What is the Stock P/E of Fischer Medical Ventures Ltd?

The Stock P/E of Fischer Medical Ventures Ltd is 1,036.

What is the Book Value of Fischer Medical Ventures Ltd?

The Book Value of Fischer Medical Ventures Ltd is 52.9.

What is the Dividend Yield of Fischer Medical Ventures Ltd?

The Dividend Yield of Fischer Medical Ventures Ltd is 0.00 %.

What is the ROCE of Fischer Medical Ventures Ltd?

The ROCE of Fischer Medical Ventures Ltd is 1.07 %.

What is the ROE of Fischer Medical Ventures Ltd?

The ROE of Fischer Medical Ventures Ltd is 0.70 %.

What is the Face Value of Fischer Medical Ventures Ltd?

The Face Value of Fischer Medical Ventures Ltd is 10.0.